Study of fingolimod, nitric oxide inhibitor, and P-glycoprotein inhibitor in modulating the P-glycoprotein expression via an endothelin-sphingolipid pathway in an animal model of pharmacoresistant epilepsy.

Indian J Pharmacol · 2023 · PMC10751529 · PMID 37929409

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantP < 0.01actually significant

The treatment with Fingolimod reversed the decrease in SOD levels in a dose-dependent fashion with a highly significant increase at 1 mg/kg dose ( P < 0.01), followed by 0.5 mg/kg ( P < 0.05) in contrast to the PB-resistant group.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.